Gag-Pol supplied in trans is efficiently packaged and supports viral function in human immunodeficiency virus type 1 by Hill, M. K. et al.
	 	
	
 
 
 
This is the published version:  
 
	
Hill,	M.	K.,	Hooker,	C.	W.,	Harrich,	D.,	Crowe,	S.	M.	and	Mak,	J.	2001,	Gag‐Pol	supplied	in	trans	is	
efficiently	packaged	and	supports	viral	function	in	human	immunodeficiency	virus	type	1,	Journal	
of	virology,	vol.	75,	no.	15,	pp.	6835‐6840.	
	
Available from Deakin Research Online: 
 
http://hdl.handle.net/10536/DRO/DU:30047532	
	
	
Reproduced	with	the	kind	permission	of	the	copyright	owner.		
	
Copyright	:	2001,	American	Society	for	Microbiology	
JOURNAL OF VIROLOGY,
0022-538X/01/$04.0010 DOI: 10.1128/JVI.75.15.6835–6840.2001
Aug. 2001, p. 6835–6840 Vol. 75, No. 15
Copyright © 2001, American Society for Microbiology. All Rights Reserved.
Gag-Pol Supplied in trans Is Efficiently Packaged and Supports
Viral Function in Human Immunodeficiency Virus Type 1
M. K. HILL,1 C. W. HOOKER,2 D. HARRICH,2 S. M. CROWE,1 AND J. MAK1*
AIDS Pathogenesis Research Unit, Macfarlane Burnet Centre for Medical Research, Fairfield, Victoria 3078,1 and Sir
Albert Sakzewski Virus Research Centre, Royal Children’s Hospital, Herston, Queensland 4029,2 Australia
Received 18 January 2001/Accepted 12 April 2001
The intracellular trafficking and subsequent incorporation of Gag-Pol into human immunodeficiency virus
type 1 (HIV-1) remains poorly defined. Gag-Pol is encoded by the same mRNA as Gag and is generated by
ribosomal frameshifting. The multimerization of Gag and Gag-Pol is an essential step in the formation of
infectious viral particles. In this study, we examined whether the interaction between Gag and Gag-Pol is
initiated during protein translation in order to facilitate the trafficking and subsequent packaging of Gag-Pol
into the virion. A conditional cotransfection system was developed in which virion formation required the
coexpression of two HIV-1-based plasmids, one that produces both Gag and Gag-Pol and one that only
produces Gag-Pol. The Gag-Pol proteins were either immunotagged with a His epitope or functionally tagged
with a mutation (K65R) in reverse transcriptase that is associated with drug resistance. Gag-Pol packaging
was assessed to determine whether the Gag-Pol incorporated into the virion was preferentially packaged from
the plasmid that expressed both Gag and Gag-Pol or whether it could be packaged from either plasmid. Our
data show that translation of Gag and Gag-Pol from the same mRNA is not critical for virion packaging of the
Gag-Pol polyprotein or for viral function.
The gag and pol genes of human immunodeficiency virus
type 1 (HIV-1) are initially translated as polyproteins, which
are later cleaved by the viral protease to produce mature viri-
ons. Gag is expressed as a 55-kDa precursor (Pr55Gag), and Pol
is expressed in the form of a 160-kDa Gag-Pol fusion protein
(Pr160Gag-Pol). These precursor polyproteins are encoded by
the same mRNA but are not synthesized at the same rate. The
pol gene lacks its own initiation codon and is in the 21 reading
frame with respect to gag. The Gag-Pol fusion protein is syn-
thesized as a result of an infrequent ribosomal frameshifting
event, wherein the ribosomes translating gag slip back one
nucleotide into the pol reading frame (20). Ribosomal frame-
shifting generates 20 times as much Gag as Gag-Pol, support-
ing the greater requirement for structural proteins over enzy-
matic proteins during viral assembly. Maintenance of the 20:1
ratio of Gag to Gag-Pol is critical for viral infectivity and RNA
dimerization (29).
Several lines of indirect evidence suggest that the Gag and
Gag-Pol precursor proteins and the viral genomic RNA form
an assembly complex in the cytoplasm that is transported as a
unit to the cell membrane for viral assembly and budding. Gag
and Gag-Pol are translated from the unspliced viral genomic
RNA on free polyribosomes in the cell cytoplasm, creating a
high local concentration of nascent Gag and Gag-Pol mole-
cules alongside the viral RNA. The finding that the assembly of
HIV-1 and other retroviruses is facilitated by nucleic acids (4,
6, 7, 10, 26), combined with the nucleic acid binding properties
of the nucleocapsid (NC) region of Gag (for a review, see
reference 13), indicates an important role for interactions be-
tween Gag and viral genomic RNA in the assembly process.
Although retroviral assembly can occur independently of
genomic RNA packaging (as shown by HIV-1 packaging signal
[Psi] deletion mutants that generate empty particles [for a
review, see reference 1]), in these cases assembly may have
been promoted by the host cell’s nucleic acids (10).
It is generally believed that Gag-Pol is incorporated into the
virion via interactions with Gag (19, 31, 33), and there is evi-
dence to suggest that the multimerization of Gag and Gag-Pol
occurs prior to their association with the cell membrane. For
HIV-1 assembly to occur, Gag must undergo myristoylation
(14), a step that is critical for the transport of Gag to the
plasma membrane. However, both nonmyristoylated Gag and
nonmyristoylated Gag-Pol can be packaged into progeny viri-
ons when coexpressed with myristoylated Gag (9, 28, 30). Ve-
locity sedimentation analysis of Gag-only particles has shown
that both myristoylated and nonmyristoylated Gag proteins
can assemble into multimeric assembly intermediates, but my-
ristoylation is required to complete virus-like particle forma-
tion (24, 27). Furthermore, Lee et al. (22, 23) have reported the
formation of Gag and Gag-Pol precursor complexes in the
cytoplasm of HIV-1-infected CD41 T cells.
Experiments using Moloney murine leukemia virus have
shown that the Gag portion of Gag-Pol is not required for the
packaging of Pol proteins. However, a lower level of reverse
transcriptase (RT) activity was observed in the resulting virions
than in wild-type virions (3), suggesting a deficient packaging
of Pol. In HIV-1, the provision of Gag in trans to Gag-Pol
results in the formation of virus-like particles containing both
Gag and Gag-Pol (28, 30). Taken together, these investigations
show that the packaging of Gag-Pol does not require Gag and
Gag-Pol to be synthesized from the same mRNA. However,
these studies do not establish if the multimerization of Gag and
Gag-Pol preferentially occurs during protein translation as a
means of facilitating the transport and subsequent packaging
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of Gag-Pol into progeny virions. In this study, we have assessed
whether the incorporation of Gag-Pol that is supplied in trans
is as efficient as the incorporation of Gag-Pol that is synthe-
sized from the same mRNA as Gag. Using a conditional co-
transfection system designed to distinguish between packaged
Gag-Pol proteins expressed either from the same construct
that expresses Gag or from a separate construct, we observed
that Gag and Gag-Pol multimerization during translation from
a single mRNA molecule is not critical for virion packaging of
the Gag-Pol polyprotein. Furthermore, we found that an in-
teraction between Gag and Gag-Pol proteins generated from
the same mRNA is not necessary to generate functional viri-
ons.
MATERIALS AND METHODS
Construction of DNA plasmids. The HIV-1 DNA constructs used in this study
were derived from either the full-length wild-type HIV-1 plasmid HXB2-BH10
(32) or the luciferase reporter plasmid pNL4-3.Luc.R- E- (12). pNL4-3.Luc.R-
E- was obtained through the AIDS Research and Reference Reagent Program,
Division of AIDS, National Institutes of Health, from N. Landau. For all exper-
iments we used two fundamental HIV constructs, one that expresses both Gag
and Gag-Pol but with a functional deletion in rev (G:GP), and one that expresses
only Gag-Pol due to a frameshift mutation that allows continuous expression of
Gag-Pol and bypasses the Gag termination codon (GP). G:GP was created by
deleting the majority of the second half of exon 2 of rev in HXB2-BH10 as
previously described (29). GP was constructed in HXB2-BH10 as previously
described (29) to alter the heptanucleotide sequence that is responsible for 21
ribosomal frameshifting, by direct base changes and the addition of an extra
nucleotide (59-TTTTTTA-39359-CTTCCTCA-39).
The histidine (His) epitope tag was introduced into the 39 end of integrase
(IN) in the HXB2-BH10-based G:GP and GP plasmids. An MluI site was intro-
duced into IN to replace the existing BspMI site located near the 39 end of IN
(59-TGGCAG-39359-ACGCGT-39), using PCR stitch mutagenesis, a technique
that introduces mutations via the PCR primers as previously described (16).
Subsequent digestion with MluI and ligation with a double-stranded DNA
adapter complementary to the MluI cleavage site and containing the His epitope
(59-CAT CAC CAT CAC CAT CAC-39) generated the G:GPHis and GPHis
plasmids. The K65R mutation is a lysine-to-arginine change at amino acid 65
in HIV-1 RT that is associated with resistance to the antiretroviral drug
(2)-b-29,39-dideoxy-39-thiacytidine (3TC, lamivudine) (15). This mutation
(AAA3AGA) was introduced into the HXB2-BH10-based G:GP and the GP
plasmids by PCR stitch mutagenesis to generate G:GPK65R and GPK65R. A
functional deletion in rev was introduced into pNL4-3-Luc.R- E- by digestion
with BamHI, which is located in the second exon of rev, followed by S1 nuclease
treatment according to the manufacturer’s instructions (Boehringer Mannheim)
to remove 25 bp and generate Luc.Rev-. The frameshift mutation and/or the
K65R mutation were introduced by subcloning from the G:GP, G:GPK65R, GP,
and GPK65R into Luc.Rev- or pNL4-3-Luc.R- E-, generating Luc.G:GP, Luc.G:
GPK65R, Luc.GP, and Luc.GPK65R. All PCRs were conducted using the high-
fidelity DNA polymerase enzyme Pfx as specified by the manufacturer (Gibco
BRL). All constructs were sequenced to confirm the presence of the desired
mutations.
Cotransfection and virus production. The G:GP and GP plasmids were co-
transfected at a ratio of 20 mg of G:GP to 1 mg of GP in order to generate equal
levels of Gag-Pol proteins derived from all constructs. The Luc.G:GP and
Luc.GP plasmids were also cotransfected at a ratio of 20 to 1, and 5 mg of
pVSV-G (a kind gift from J. C. Burns, University of California, San Diego) was
included to provide a viral envelope that would enable infection (5). The calcium
phosphate coprecipitation method was used for the transient transfection of
293T cells. Supernatants were collected at 36 h posttransfection and centrifuged
for 30 min at 3,000 rpm (Beckman model GS-6) to remove cellular debris.
Virions were purified and concentrated by ultracentrifugation (Beckman model
L-90, SW41 rotor) at 35,000 rpm for 1 h at 4°C through a 20% sucrose cushion.
For protein isolation, viral pellets were resuspended in 50 ml of 23 Tris-buffered
saline lysis buffer containing 1% Nonidet P-40, 20 mM phenylmethylsulfonyl
fluoride, 1 mM pepstatin, and 1 mM leupeptin. For use in the reverse transcrip-
tion assay and the natural endogenous reverse transcription (NERT) assay, viral
pellets were resuspended in Tris-EDTA. Virus production from transfections
was quantified by measuring p24 antigen levels in the pelleted virion stocks and
the cell culture supernatants (HIV-1 p24 assay; Abbott Laboratories).
Western blot analysis. Protein samples were resolved by sodium dodecyl
sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) (10% gel) and trans-
ferred to a nitrocellulose membrane (Hybond C; Amersham Pharmacia Bio-
tech). Western blot analysis was carried out as previously described (29), using an
a-RT antibody (NEN) to detect p66 RT, an a-His antibody (Qiagen) to detect
the His-tagged Gag-Pol polyproteins, and pooled sera from HIV-infected pa-
tients to detect total HIV-1 viral proteins. An ECL (enhanced chemilumines-
cence) detection kit (Amersham Pharmacia Biotech) was used to visualize the
proteins for assessment by laser densitometry.
Cell-free RT assay. The cell-free RT assay was adapted from a method de-
scribed by Boyer et al. (2). For each sample, 0.2 ml of a 20-mg/ml stock of M13-47
sequencing primer (New England Biolabs) was annealed to 0.25 mg of single-
stranded M13mp18 DNA (New England Biolabs) by heating to 95°C for 5 min
and then slowly cooling to room temperature. In a final volume of 60 ml, each
sample contained 10 ml of Nonidet P-40, pelleted virus (5 ng of p24), 25 mM
Tris-Cl (pH 8.0), 75 mM KCl, 8.0 mM MgCl2, 2 mM dithiothreitol, 100 mg of
bovine serum albumin per ml, 10 mM CHAPS {3-[(3-cholamidopropyl)-dimeth-
ylammonio]-1-propanesulfonate}, 10 mM each dATP, dGTP, and dCTP, 5 mM
dTTP, 0.5 mCi of [a-33P]dTTP (NEN), and 3TC-triphosphate (Moravek Bio-
chemicals), which was routinely used at a concentration of 2.5, 5, or 15 mM. The
samples were incubated for 1 h at 37°C, and then 8 ml of each reaction was
spotted onto DE81 filter paper, which was washed six times in 23 SSC (13 SSC
is 0.15 M NaCl plus 0.015 M sodium citrate and then analyzed on a microbeta
counter (Wallac).
NERT assay. The NERT assay was carried out as previously described (17).
Briefly, sucrose-purified virus (typically 100 pg of p24) was supplemented with
MgCl2 and DNase I and incubated at 37°C for 90 min in the presence and
absence of deoxynucleoside triphosphates. Reverse transcription was terminated
by the addition of EDTA and proteinase K followed by boiling for 10 min.
Stopped reactions were assayed for negative-strand strong-stop DNA by PCR.
Standard curves were generated by amplifying serial dilutions of an HIV-1
proviral plasmid, and all PCRs were performed in the linear range of the assay.
Single-round infection analyses with the pNL4-3-Luc.R- E- constructs.
Cleared viral supernatants containing 10 ng of p24 were adjusted to 200 ml with
culture medium and incubated with 106 MT-2 cells for 2 h. The virus was then
removed by washing the infected cells once with phosphate-buffered saline with-
out calcium chloride and magnesium chloride and resuspending them in 1 ml of
culture medium. The luciferase activity in the cells was determined 48 h postin-
fection using a luciferase assay kit (Promega). In experiments conducted in the
presence of 3TC (obtained from the AIDS Research and Reference Reagent
Program, Division of AIDS, National Institutes of Health), the MT-2 cells were
incubated with 50 nM 3TC for 4 h prior to infection, 2 h during infection, and
48 h postinfection. The mean 50% inhibitory concentration of 3TC, which was
shown to inhibit several different strains of HIV-1 in primary cells, ranges
between 2.5 nM and 0.67 mM (11). Trypan blue staining was used to monitor
cytotoxic effects of 3TC, and no differences were observed between control and
3TC-treated cultures.
RESULTS AND DISCUSSION
G:GP and GP were cotransfected to determine whether the
interaction between Gag and Gag-Pol is initiated during pro-
tein translation. If Gag and Gag-Pol interact during their syn-
thesis from a single mRNA molecule to facilitate Gag-Pol
packaging, the progeny virions would be expected to contain
primarily Gag-Pol from the plasmid synthesizing both Gag and
Gag-Pol. Conversely, the progeny virions will contain similar
levels of Gag-Pol proteins from both plasmids if the Gag/Gag-
Pol interaction can occur efficiently when Gag-Pol is supplied
in trans.
Development of a conditional cotransfection system. The
conditional cotransfection system allows viral particle forma-
tion only when both cotransfected plasmids are simultaneously
expressed in the same cell. This system takes advantage of the
fact that both Gag and Rev are required for viral particle
formation. As Rev is required for the transport of genomic
RNA from the nucleus to the cytoplasm (for a review, see
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reference 18), transfection of a Rev-deficient HIV-1 plasmid
(G:GP) alone results in viral mRNA being trapped in the
nucleus. Similarly, viral particles will not be formed when GP
is transfected alone, as Gag is required for virion production.
Accordingly, when either G:GP or GP was transfected into
293T cells, no pelletable HIV-1 proteins were detected (data
not shown). As the natural ratio of Gag to Gag-Pol synthesis is
20:1, the two plasmids were cotransfected at a ratio of 20 G:GP
to 1 GP (based on DNA concentration) so that equivalent
amounts of Gag-Pol proteins would be derived from all con-
structs. This enables a direct comparison of packaged Gag-Pol
synthesized from either G:GP or GP. The HIV-1 constructs
used in these analyses are depicted in Fig. 1A.
The Gag-Pol proteins were tagged with a His epitope that
was inserted into the C-terminal region of IN (Fig. 1B) to allow
semiquantitative assessment of Gag-Pol incorporation by
Western blot analysis. Two types of viral particles, G:GPHis/GP
and G:GP/GPHis, were obtained by cotransfection. If Gag and
Gag-Pol interact during translation to facilitate Gag-Pol pack-
aging, the G:GPHis/GP virion should incorporate greater levels
of His-tagged Gag-Pol than G:GP/GPHis. As the His tag may
alter Gag-Pol packaging by changing the conformation of the
Gag-Pol protein, an alternative labeling system in which Gag-
Pol proteins were functionally tagged with a K65R mutation in
RT was also used (Fig. 1B). This mutation mediates resistance
to 3TC, enabling wild-type Gag-Pol and K65R Gag-Pol to be
differentiated in the presence of the drug. The K65R mutation
was chosen because it maintains a drug-resistant phenotype
when used in a cell-free RT assay (15). Four types of virus were
produced through cotransfection: the drug-sensitive control
G:GP/GP, the drug-resistant control G:GPK65R/GPK65R, and
the two test cases G:GP/GPK65R and G:GPK65R/GP. If Gag
and Gag-Pol interact during translation, Gag and Gag-Pol in
progeny virions will be preferentially derived from the G:GP
plasmid that expresses both proteins, so that one would expect
G:GP/GPK65R to be drug sensitive and G:GPK65R/GP to be
drug resistant. If Gag-Pol can be packaged with equivalent
efficiency when translated with Gag or when translated alone,
both types of virion should be similarly susceptible to 3TC-
triphosphate.
Gag and Gag-Pol do not interact during translation from
the same mRNA to facilitate Gag-Pol packaging. Epitope tag-
ging of the Gag-Pol proteins was used to ascertain the amounts
of packaged Gag-Pol derived from either the G:GP or the GP
plasmid. G:GPHis/GP and G:GP/GPHis viral particles obtained
by cotransfection of 293T cells were concentrated by ultracen-
trifugation and resuspended in protein lysis buffer. A protein
dilution series of each virus was resolved by SDS-PAGE for
Western blotting, and the resultant blots were hybridized suc-
cessively with a-RT, a-His, and pooled sera from HIV-1-in-
fected patients. RT levels provided a comparative measure of
the total amount of HIV-1 Gag-Pol polyprotein in each virus
stock, and the concentration of a-His reactive protein reflects
the amount of Gag-Pol packaged from a particular plasmid
(Fig. 2). For the representative experiment depicted in Fig. 2,
the His signals (standardized to equivalent levels of RT) were
993, 421, and 309 (densitometry units) for the three dilutions of
G:GP/GPHis and 906, 478, and 270 for the three dilutions of
G:GPHis/GP, indicating similar efficiencies of Gag-Pol packag-
ing from the two plasmids. Hybridization with the pooled pa-
tient sera indicated that there were no obvious differences in
FIG. 1. (A) The HIV-based constructs used for all cotransfections. (B) Schematic representation of the Gag and Gag-Pol polyproteins showing
the major domains and the sites of labeling with either the His epitope or the K65R mutation. LTR, long terminal repeat; MA, matrix; CA, capsid;
NC, nucleocapsid; PR, protease.
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total HIV-1 protein expression levels or patterns between the
two viruses (data not shown).
G:GP/GP, G:GPK65R/GPK65R, G:GP/GPK65R, and G:GPK65R/
GP virions were also generated by cotransfection of 293T cells.
The four virion samples were normalized on the basis of p24
levels, and a cell-free RT assay was used to determine RT
activity in the presence and absence of 3TC-triphosphate, a
competitive inhibitor of dCTP incorporation into the nascent
DNA chain. Initially three concentrations (2.5, 5, and 15 mM)
of 3TC-triphosphate were selected that gave clearly distin-
guishable differences between the drug-sensitive control virion
G:GP/GP and the drug-resistant control virion G:GPK65R/
GPK65R. Averaged data from three assays of virions produced
from three separate transfections are shown in Fig. 3. The
levels of 3TC-triphosphate inhibition of RT activity in the two
test cases (G:GP/GPK65R and G:GPK65R/GP) were very similar
to each other. While not readily distinguishable from the drug-
susceptible control, the level of inhibition of RT activity for
G:GP/GPK65R and G:GPK65R/GP was clearly distinct from that
of the drug-resistant control. 3TC-triphosphate concentrations
between 0.5 and 16 mM were used to address the possibility
that lower drug concentrations may better determine a pref-
erence for Gag-Pol packaging in a population of both wild-type
and drug-resistant Gag-Pol polyproteins. RT enzymes from
G:GP/GPK65R and G:GPK65R/GP displayed very similar levels
of 3TC-triphosphate susceptibility. A virus dilution series dem-
onstrated that our results were not influenced by saturating
concentrations of RT enzyme (data not shown). Overall, the
RT assay results showed that both drug-sensitive and drug-
resistant Gag-Pol proteins were packaged into both G:GP/
GPK65R and G:GPK65R/GP.
Consequently, no preference involving Gag-Pol encapsida-
tion could be distinguished by either Western blot analysis with
His-tagged Gag-Pol or RT assays with functionally labeled
Gag-Pol. These results are in agreement with those of Park and
Morrow (28) and Smith et al. (30), who demonstrated that
Gag-Pol could be incorporated into the virion when supplied in
trans to Gag. Moreover, our data show that the Gag-Pol
polyprotein is efficiently packaged into the virion irrespective
of being translated with Gag or translated alone.
Gag and Gag-Pol interaction during translation from the
same mRNA is not required for endogenous reverse transcrip-
tion or viral infectivity. To determine whether or not an inter-
action between Gag and Gag-Pol at the time of translation is
important for correct protein folding and the proper molecular
arrangement of proteins within the virion, functional compe-
tence of the K65R labeled viruses was assessed by NERT and
viral infectivity assays. The NERT assay measures the endog-
enous RT activity within intact virions, which is thought to
reflect the viruses’ ability to successfully initiate infection (35,
36). The NERT assays (Fig. 4A) show that the drug-sensitive
(G:GP/GP) and the drug-resistant (G:GPK65R/GPK65R) con-
trols are affected by 3TC-triphosphate as anticipated, with
G:GPK65R/GPK65R being two- to threefold more resistant to
3TC-triphosphate than G:GP/GP (Fig. 4A). However, the two
test cases, G:GP/GPK65R and G:GPK65R/GP, displayed similar
levels of NERT activity; both were approximately 1.3-fold
more resistant than the drug-sensitive control and 0.5-fold less
resistant than the drug-resistant control (Fig. 4A). Viral infec-
tivity was assessed from the infection of MT-2 cells in the
presence and absence of 3TC via the luciferase reporter gene.
The controls were clearly separable on the basis of drug re-
sponse, with the Luc.G:GP/Luc.GP virions being 2- to 2.5-fold
more susceptible to 3TC than the Luc.G:GPK65R/Luc.GPK65R
virions. However, the two test samples, Luc.G:GP/Luc.GPK65R
Luc.G:GPK65R/Luc.GP, consistently generated similar levels of
luciferase activity, with both approximately 1.3-fold more re-
sistant than the drug-sensitive control and 0.5-fold less resis-
tant than the drug-resistant control (Fig. 4B).
The results of both the NERT and the viral infectivity assays
were consistent with the Gag-Pol packaging data described
above, which established that Gag-Pol was efficiently packaged
when supplied in trans. Moreover, the NERT and viral infec-
tivity assays show that an interaction between Gag and Gag-Pol
during translation is not essential for the function of Gag-Pol
proteins in virions. The packaging of the retroviral enzymes in
FIG. 2. Western blot analysis of virion lysates produced from co-
transfections in 293T cells to produce two virion types, G:GPHis/GP
and G:GP/GPHis. Virion lysates were analyzed by SDS-PAGE with
twofold dilutions of each lysate alongside the mock and the wild-type
HXB2-BH10 control. RT (p66) is indicative of the overall level of
Gag-Pol protein. His-tagged IN reflects the level of one particular
Gag-Pol population in each virus type.
FIG. 3. Cell-free RT assay performed in the presence and absence
of 3TC-triphosphate on four virion types: the drug-sensitive G:GP/GP
and drug-resistant G:GPK65R/GPK65R controls and the two test cases,
G:GP/GPK65R and G:GPK65R/GP. Virions were produced by co-trans-
fection in 293T cells and were normalized on the basis of p24 levels.
Inhibition of RT activity is presented relative to a no-drug control for
three 3TC-triphosphate concentrations. The data shown are the aver-
ages of assays performed with virions produced from three separate
transfections.
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the form of a precursor protein is in itself suggestive of a role
for Gag-Pol in coordinating the placement of the viral enzymes
within the mature virion. Functional RT and IN proteins can
be packaged when supplied in trans as Vpr fusion proteins to
generate infectious virions (25, 34). However, Wu et al. (34)
found that the levels of infection achieved when the proteins
were supplied individually as Vpr-RT and Vpr-IN did not
reach those of virions complemented by RT-IN supplied in
fusion, Vpr-RT-IN, which in turn were not as infectious as
wild-type virions. Thus, it remains likely that the expression of
the Pol proteins in the form of a precursor is important both
for the control of expression in required ratios and the coor-
dinated arrangement of viral enzymes in the virion.
The precise steps and timing of virion assembly and matu-
ration are not clearly understood. Together with the 1,500 or
so Gag molecules present in an HIV-1 virion, 70 Gag-Pol
proteins must also be incorporated. While our results indicate
that the multimerization of Gag and Gag-Pol is not reliant on
Gag-Pol being synthesized from the same mRNA as Gag, they
do not, however, rule out the possibility that the Gag and
Gag-Pol interaction occurs during translation between protein
molecules on adjacent separate polysomes. Consequently,
Gag-Pol may still be incorporated into a viral assembly com-
plex formed in the context of the polysome. While Gag drives
viral assembly and Gag alone will form virus-like particles,
expression of Gag-Pol in the absence of Gag generates pro-
cessed Gag and Pol proteins; however, no progeny virions are
formed for study in systems equivalent to those of Gag-only
particles (30). Kaye and Lever (21) have reported that Gag-Pol
expressed alone in a T-cell line will produce pelletable Gag-Pol
and negligible amounts of viral genomic RNA, but there is no
further evidence to suggest that virus-like particles are formed
in the absence of Gag. The difficulty involved in separating the
functions of the shared regions of Gag and Gag-Pol provides a
further obstacle in addressing the process of Gag-Pol assembly.
The cotransfection and Gag-Pol labeling system described here
enable independent examination of Gag-Pol packaging, as al-
terations to the Gag-Pol-only expression vector (GP) that af-
fect Gag-Pol packaging can be monitored by changes in the
Gag-Pol packaging profiles. This system could also be used to
investigate Gag-Pol interactions not only with Gag but also
with RNA and host cellular factors involved in viral assembly.
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